Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Subcutaneous insulin Clear all
Completed Phase 1 Interventional

Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

NCT01153100
View directory record Official record
Conditions
Diabetes
Interventions
Glargine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy

NCT01474538
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Lispro, Insulin Aspart
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Little Rock, Arkansas • Jacksonville, Florida • West Palm Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional Results available

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

NCT00886821
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CVX-096
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Miami Gardens, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 27, 2026, 5:55 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

NCT03307512
View directory record Official record
Conditions
Safety and Tolerability
Interventions
inhaled human insulin, Insulin Lispro (Humalog U-100)
Drug
Lead sponsor
Dance Biopharm Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers

NCT05790681
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
21
States / cities
Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

NCT01336751
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2011 · Synced Sep 27, 2026, 5:55 PM EDT
Active, not recruiting Phase 2 Interventional

Effects of GRA in Patients With Type 1

NCT04779645
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
REMD-477, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)

NCT00596934
View directory record Official record
Conditions
Fatty Liver Disease, Nonalcoholic
Interventions
metreleptin
Drug
Lead sponsor
Elif Oral
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3209590 in Participants With Type 1 Diabetes

NCT04450407
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY3209590, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Concord, California • Fresno, California • Ventura, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 4 Interventional Results available

Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes

NCT05243628
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Biological · Device
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Loma Linda, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Insulin-Only Bionic Pancreas Bridging Study

NCT03565666
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, iLet Bionic Pancreas insulin-only configuration with Fiasp, Usual care
Device · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

NCT01680341
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Goodyear, Arizona • Anaheim, California • Greenbrae, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional

Afrezza® INHALE-1 Study in Pediatrics

NCT04974528
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Afrezza, Rapid-acting Insulin Analog, Basal Insulin
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
4 Years to 17 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
39
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

NCT01814137
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin degludec, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

NCT03436498
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart SAR341402, Insulin aspart
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Little Rock, Arkansas • Denver, Colorado • West Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 27, 2026, 5:55 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

NCT06657209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions
Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone
Procedure · Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.

NCT00143338
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Fresno, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2008 · Synced Sep 27, 2026, 5:55 PM EDT
Completed No phase listed Observational

Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System

NCT02073058
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
No treatment
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Rett Syndrome With Recombinant Human IGF-1

NCT01777542
View directory record Official record
Conditions
Rett Syndrome
Interventions
Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2018 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

NCT00993473
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 6 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

NCT02738151
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
74
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 4 Interventional Results available

Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir

NCT00717288
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Detemir
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Sep 27, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

NCT03977727
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Fiasp®, Novolog®, 670G hybrid closed loop continuous subcutaneous insulin infusion system
Drug · Device
Lead sponsor
Texas Diabetes & Endocrinology, P.A.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 27, 2026, 5:55 PM EDT